Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CERS
HOLDCerus Corporation · Healthcare · United States · $587M · Avg Vol: $8M/d
COMPANY DESCRIPTION
Cerus Corporation is a biomedical products company focused on blood safety, developing and commercializing the INTERCEPT Blood System, a proprietary technology designed to inactivate a broad spectrum of pathogens in transfused blood components. Its competitive moat lies in its patented technology, offering a critical safety enhancement in transfusion medicine with significant regulatory approvals and growing adoption by blood centers globally. Cerus is a niche leader, driving innovation in blood component safety with a unique and effective solution.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 162.0M | 156.4M | 180.3M | 206.1M | 8.4% | 216.6M | 238.1M | 259.8M | 12.3% |
| EPS | -0.24 | -0.21 | -0.11 | -0.08 | — | -0.05 | -0.03 | — | — |
| Shares | 177.6M | 181.2M | 185.8M | 192.1M | +8.2% | 200.4M | — | — | — |
| Debt | 87.2M | 96.0M | 98.1M | 96.9M | 3.6% | 97.4M | — | — | — |
| Equity | 67.6M | 52.6M | 56.1M | 64.2M | -1.7% | — | — | — | — |
| Op CF | -25.6M | -43.2M | 11.4M | 4.8M | -57.4% | 2.6M | — | — | — |
| Inv CF | 8.5M | 8.6M | -8.1M | -6.2M | — | — | — | — | — |
| Fin CF | 4.2M | 10.7M | 5.0M | 0.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CERS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CERS | Cerus Corporation(you) | $587M | 50 | HOLD |
| KIDS | OrthoPediatrics Corp. | $485M | 54 | HOLD |
| OFIX | Orthofix Medical Inc. | $455M | 54 | HOLD |
| CTKB | Cytek Biosciences, Inc. | $576M | 41 | HOLD |
| SIBN | SI-BONE, Inc. | $737M | 43 | HOLD |
| VREX | Varex Imaging Corporation | $460M | 56 | HOLD |
| QDEL | QuidelOrtho Corporation | $1.1B | 48 | HOLD |
| MASS | 908 Devices Inc. | $293M | 52 | HOLD |
| NPCE | NeuroPace, Inc. | $505M | 34 | SELL |
| INSP | Inspire Medical Systems, Inc. | $1.4B | 56 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%